November 16, 2018
FEDERAL ADVOCACY ALERT
340B Drug Ceiling Price Effective Date - Comments Due Nov. 23
On November 2, the Health Resources and Services Administration (HRSA) published a proposed rule changing the effective date for the 340B Drug Program ceiling price and drug manufacturers’ final rule. The rule describes how ceiling prices must be calculated and allows the federal government to levy civil monetary penalties against drug companies that intentionally overcharge 340B providers. AHA, the Association of American Medical Colleges, America's Essential Hospitals, 340B Health and three hospital systems filed a lawsuit challenging the Department of Health and Human Services for failure to implement this final rule. Facing deadlines for responding to the lawsuit, HRSA proposed a Jan. 1, 2019 compliance date for its final rule.
ACTION REQUESTED: IHA, working with AHA, is asking that all its 340B member hospitals submit comments to HRSA urging the agency to stand by its commitment and publish the final rule in a timely manner. Click here for a sample letter that you can customize to compose your letter. All comments must be received on or before Nov. 23. You can file your comment letter with HRSA by clicking here. IHA will file its own comment letter, which will be available on the IHA website once it is submitted.
Last week, AHA sent an alert to its 340B hospital members asking that they submit comments to HRSA urging the agency to stand by its commitment and to publish the final rule in time to meet the Jan. 1 deadline.
If you have any questions for AHA, please contact:
If you have questions or comments for IHA, please contact: Tom Jendro.